In cell therapy applications, commonly employed cell purification platforms for large-scale isolation of immune or stem cells separate cells based on a single cell surface antigen. Enrichment based on ...

As demand for CAR T therapies strain traditional manufacturing, Autolus Therapeutics has tapped Cellares to evaluate whether that company’s automated Cell Shuttle platform can support expanded ...

Officials at Mytos, which is automating cell manufacturing, launched its automated contract development and manufacturing organization (CDMO), offering to overcome one of what they call regenerative ...

The first GMP cell therapy product ever manufactured for clinical use on the Cell Shuttle™ and released using Cell Q™, is expected to be infused into patients within Cabaletta’s RESET™ clinical trial ...

SOUTH SAN FRANCISCO, Calif. & LONDON--(BUSINESS WIRE)--Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation ...

Cellular Origins, a TTP Company, focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), today announced the acquisition of the ACTIA (Autologous ...

Automation in cell and gene therapy manufacturing promises lower costs, improved efficiency, and expanded access to ...

The "Cell and Gene Therapy Manufacturing Market -- Growth, Share, Opportunities & Competitive Analysis, 2024 -- 2032" report has been added to the Credence Research Inc. offering. The global Cell and ...

To reduce engineering time and get their products to market faster, many device makers are turning to standardized automated ...

Autolus will evaluate Cellares’ fully automated, high-throughput manufacturing platform in preparation for expansion into new indications Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage ...